Work

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC

Year: 2016

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2016.09.010

Authors: Todd M. Bauer, David Spigel, Neal Ready, Daniel Morgensztern, Bonnie S. Glisson, Lauren A. Byers, Howard Burris, Francisco Robert, Donald K. Strickland, Maria C. Pietanza, Ramaswamy Govindan, Scott J. Dylla, Stanford Peng, Charles Rudin

Institutions: Sarah Cannon, Tennessee Oncology, Duke Medical Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, Memorial Sloan Kettering Cancer Center, AbbVie (United States)

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2539720888

FWCI: 1.55

Cites:

Cited by: 13

Related to: 10